ArticleChemistry & biodiversity2026
In Vivo Evaluation of the Analgesic Effects of Orientin With Possible Underlying Mechanisms.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Orientin is a water-soluble flavonoid C-glycoside present in various medicinal plants and known for its diverse pharmacological activities. The present study aimed to evaluate the acute antinociceptive effects of orientin and to investigate the involvement of adrenergic, opioidergic, cannabinoid systems, and ATP-sensitive potassium channels in these effects. Orientin (50, 100, and 200 mg/kg, i.p.) was administered to mice. Central antinociceptive activity was assessed using the hot-plate and tail-immersion tests, while peripheral activity was evaluated using the acetic acid-induced writhing test. To explore the underlying mechanisms, mice were pretreated with yohimbine (α2-adrenoceptor antagonist), naloxone (μ-opioid receptor antagonist), AM251 (CB1 receptor antagonist), AM630 (CB2 receptor antagonist), or glibenclamide (KATP channel blocker) prior to orientin administration. Orientin significantly reduced nociceptive responses in all experimental models at the tested doses. All antagonists except glibenclamide significantly reversed the spinal, supraspinal, and peripheral antinociceptive effects of orientin to varying degrees. These findings suggest that α2-adrenoceptors, μ-opioid receptors, and cannabinoid CB1 and CB2 receptors contribute to the analgesic effect of orientin, whereas KATP channels do not appear to be directly involved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.